J&J succeeds in mid-stage trial for SLE therapy (JNJ:NYSE)

Johnson & Johnson (JNJ) announced on Tuesday that nipocalimab, its experimental therapy for an autoimmune condition called systemic lupus erythematosus, reached the main goal of a mid-stage trial. Based on topline data, the New Brunswick, New Jersey-based pharma giant said that its ...